SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001193125-22-218663
Filing Date
2022-08-11
Accepted
2022-08-11 16:58:52
Documents
3
Group Members
ABINGWORTH BIOVENTURES VII LPABINGWORTH LLPCARLYLE GENESIS UK LLCCARLYLE HOLDINGS I GP INC.CARLYLE HOLDINGS I GP SUB L.L.C.CARLYLE HOLDINGS I L.P.CARLYLE INVESTMENT MANAGEMENT L.L.C.CG SUBSIDIARY HOLDINGS L.L.C.TC GROUP, L.L.C.

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d392800dsc13da.htm SC 13D/A 200954
2 EX-99.1 d392800dex991.htm EX-99.1 13388
3 EX-99.2 d392800dex992.htm EX-99.2 11749
  Complete submission text file 0001193125-22-218663.txt   228231
Mailing Address C/O THE CARLYLE GROUP 1001 PENNSYLVANIA AVENUE, N.W. WASHINGTON DC 20004
Business Address C/O THE CARLYLE GROUP 1001 PENNSYLVANIA AVENUE, N.W. WASHINGTON DC 20004 202 729 5626
Carlyle Group Inc. (Filed by) CIK: 0001527166 (see all company filings)

IRS No.: 452832612 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A
SIC: 6282 Investment Advice

Mailing Address 3 LOCHSIDE WAY EDINBURGH X0 EH12 9DT
Business Address 3 LOCHSIDE WAY EDINBURGH X0 EH12 9DT 44-0-131-357-1111
NuCana plc (Subject) CIK: 0001709626 (see all company filings)

IRS No.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-90138 | Film No.: 221156748
SIC: 2834 Pharmaceutical Preparations